Published in Scand J Immunol on January 01, 1978
Polyclonal B-cell activation induced by extracts of Gram-negative bacteria isolated from periodontally diseased sites. Infect Immun (1981) 1.25
Spontaneous antibody-secreting human blood lymphocytes detected with a protein A plaque assay. Clin Exp Immunol (1980) 0.96
Staphylococcal peptidoglycan: T-cell-dependent mitogen and relatively T-cell-independent polyclonal B-cell activator of human lymphocytes. Infect Immun (1983) 0.95
Protein A of Staphylococcus aureus is mitogenic for IgG-bearing, but also for a subpopulation of IgM- and/or IgD-bearing human lymphocytes. Immunology (1980) 0.90
T-cell independence of immunoglobulin synthesis by human peripheral blood lymphocytes stimulated with SpA-containing staphylococci. Immunology (1980) 0.83
Mechanism of activation of human basophils by Staphylococcus aureus Cowan 1. Infect Immun (1987) 0.78
Epstein-Barr virus induced pneumococcal antibody production in man. A comparison of different lymphoid organs. Clin Exp Immunol (1984) 0.75
STUDIES OF UREA EXCRETION. III: The Influence of Body Size on Urea Output. J Clin Invest (1928) 45.56
STUDIES OF UREA EXCRETION: VI. Comparison of the Blood Urea Clearance with Certain Other Measures of Renal Function. J Clin Invest (1930) 7.46
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol (2003) 4.62
Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med (2007) 3.02
Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant (2010) 2.56
Studies on antigen-binding cells. I. The origin of reactive cells. Cell Immunol (1970) 2.53
Transplantation of porcine fetal pancreas to diabetic patients. Lancet (1994) 2.52
"Spontaneous" B cell activation due to loss of normal mouse serum suppressor. Eur J Immunol (1972) 2.38
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia (2007) 2.35
Phase-coupling of theta-gamma EEG rhythms during short-term memory processing. Int J Psychophysiol (2002) 2.09
Severe and common side-effects of amphotericin B lipid complex (Abelcet) Bone Marrow Transplant (1998) 2.05
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 1.98
Transcriptomic and proteomic patterns of systemic inflammation in on-pump and off-pump coronary artery bypass grafting. Circulation (2005) 1.83
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant (2011) 1.82
Polyclonal antibody secretion in human lymphocytes induced by killed staphylococcal bacteria and by lipopolysaccharide. Scand J Immunol (1977) 1.82
Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood (1992) 1.77
Haemophilus influenzae resides and multiplies intracellularly in human adenoid tissue as demonstrated by in situ hybridization and bacterial viability assay. Infect Immun (1994) 1.70
Xylene-free method for histological preparation: a multicentre evaluation. Lab Invest (2001) 1.70
Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol (2004) 1.66
Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant (1990) 1.65
Similar frequencies and kinetics of cytokine producing cells in murine peripheral blood and spleen. Cytokine detection by immunoassay and intracellular immunostaining. J Immunol Methods (1993) 1.60
HLA and rheumatoid arthritis. A study of five families. Tissue Antigens (1981) 1.58
Intraosseous compared to intravenous infusion of allogeneic bone marrow. Bone Marrow Transplant (1998) 1.58
No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant (2008) 1.56
HL-A antigens in sarcoidosis. Tissue Antigens (1973) 1.55
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant (2004) 1.55
Plaque-formation by non-immune and x-irradiated lymphoid cells on monolayers of mouse embryo cells. Nature (1965) 1.55
Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant (2003) 1.54
Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood (1998) 1.51
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother (1991) 1.50
Spleen cells from animals tolerant to a thymus-dependent antigen can be activated by lipopolysaccharide to synthesize antibodies against the tolerogen. J Exp Med (1976) 1.48
Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection. J Virol (1993) 1.48
Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol (2007) 1.46
Role of polyclonal activation in specific immune responses. Relevance for findings of antibody activity in various diseases. Scand J Immunol (1980) 1.46
Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant (2004) 1.45
Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Haematol (1994) 1.41
Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant (2003) 1.39
Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg (2004) 1.39
Transplantation of peripheral blood progenitor cells from unrelated donors. Transplantation (1998) 1.37
Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A (1989) 1.36
Antigen binding cells in tolerant animals. Nature (1970) 1.35
Oesophageal perforations in Iceland: a whole population study on incidence, aetiology and surgical outcome. Thorac Cardiovasc Surg (2010) 1.34
IgG subclass-associated affinity differences of specific antibodies in humans. J Immunol (1988) 1.33
In vitro assay of cell-mediated immunity: the inhibition of migration of sensitized human lymphocytes by HL-A antigens. Clin Exp Immunol (1970) 1.32
Scandiatransplant: preliminary report of a kidney exchange program. Transplant Proc (1971) 1.32
Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother (1986) 1.31
Studies on antigen-binding cells. II. Relationship to antigen-sensitive cells. Cell Immunol (1970) 1.31
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis (1986) 1.28
B-cell mitogenic effects on human lymphocytes of rabbit anti-human beta 2-microglobulin. Scand J Immunol (1975) 1.27
Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy (2009) 1.27
Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant (1998) 1.27
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis (1985) 1.25
The role of adherent cells in B and T lymphocyte activation. Immunol Rev (1978) 1.23
Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant (2008) 1.22
Drainage of thoracic duct lymph in renal transplant patients. Transplantation (1976) 1.21
Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion (1998) 1.21
Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion (1997) 1.21
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol (2006) 1.21
HLA-DR-DQ haplotypes defined by restriction fragment analysis. Correlation to serology. Hum Immunol (1987) 1.20
Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood (1992) 1.19
Bacterial colonisation with Xanthomonas maltophilia--a retrospective study in a cystic fibrosis patient population. Infection (1995) 1.19
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood (2000) 1.19
The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant (2000) 1.17
Complete heart block--another HLA B27 associated disease manifestation. Tissue Antigens (1983) 1.16
Effects of adenoidectomy: a controlled two-year follow-up. Ann Otol Rhinol Laryngol (1978) 1.16
CD13 (human aminopeptidase N) mediates human cytomegalovirus infection. J Virol (1993) 1.14
B-cell activation of peripheral blood lymphocytes from patients with chronic lymphatic leukaemia. Clin Exp Immunol (1978) 1.14
An analysis of factors predisposing to chronic graft-versus-host disease. Exp Hematol (1985) 1.13
Successful outcome of segmental human pancreatic transplantation with enteric exocrine diversion after modifications in technique. Lancet (1982) 1.12
Cytotoxicity by nonimmune allogeneic lymphoid cells. Specific suppression by antibody treatment of the lymphoid cells. J Exp Med (1967) 1.12
Only one DQ-beta restriction fragment pattern of each DR specificity is associated with insulin-dependent diabetes. J Immunol (1986) 1.11
Induction of antibody synthesis in human B lymphocytes by different polyclonal B cell activators: evaluation by direct and indirect PFC assays. Immunol Rev (1979) 1.10
No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood (2001) 1.10
G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant (2003) 1.09
Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation (1984) 1.08
High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol (2000) 1.08
Glutathione transferase in the urine: a marker for post-transplant tubular lesions. Kidney Int (1988) 1.08
Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand J Immunol (1998) 1.08
Identical-twin bone marrow transplants for leukemia. Ann Intern Med (1994) 1.07
The alpha chain, not the beta chain of HLA-DR antigens participates in activation of T cells in autologous mixed lymphocyte reaction. Immunogenetics (1982) 1.07
B cell differentiation factor in synovial fluid of patients with rheumatoid arthritis. Immunol Rev (1984) 1.07
Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant (1998) 1.07
HLA phenotypes and diabetic retinopathy. Diabetologia (1978) 1.06
Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant (2007) 1.06
Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl (1985) 1.05
Activation of human B and T lymphocytes by protein A of Staphylococcus aureus. Eur J Immunol (1978) 1.05
Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant (1997) 1.05
HLA haplotypes in families with high frequency of multiple sclerosis. Arch Neurol (1976) 1.04
Effects of some immunosuppressive procedures on myasthenia gravis. Ann N Y Acad Sci (1976) 1.04
Optimal conditions for polyclonal antibody secretion and DNA synthesis in human blood and spleen lymphocytes by lipopolysaccharide. Scand J Immunol (1978) 1.04